Marinus Pharmaceuticals (NASDAQ:MRNS) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Friday morning, Benzinga reports.

Several other analysts also recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 4th. LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Eight investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.07.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.37 on Friday. The stock has a 50 day moving average price of $1.54 and a 200 day moving average price of $1.51. Marinus Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the prior year, the firm posted ($0.61) earnings per share. On average, equities analysts anticipate that Marinus Pharmaceuticals will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at $34,000. AQR Capital Management LLC increased its position in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals in the 2nd quarter worth $64,000. Finally, Values First Advisors Inc. lifted its position in Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.